IOVA
NASDAQ · Biotechnology
Iovance Biotherapeutics Inc
$8.04
+0.30 (+3.88%)
Financial Highlights (FY 2026)
Revenue
331.94M
Net Income
-492,513,973
Gross Margin
34.3%
Profit Margin
-148.4%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 34.3% | 62.6% | 62.6% | 62.6% |
| Operating Margin | -153.1% | 8.6% | 9.3% | 8.6% |
| Profit Margin | -148.4% | 7.0% | 5.4% | 7.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 331.94M | 337.04M | 333.93M | 362.22M |
| Gross Profit | 113.79M | 210.86M | 208.91M | 226.61M |
| Operating Income | -508,139,697 | 29.04M | 30.95M | 31.15M |
| Net Income | -492,513,973 | 23.64M | 18.09M | 27.70M |
| Gross Margin | 34.3% | 62.6% | 62.6% | 62.6% |
| Operating Margin | -153.1% | 8.6% | 9.3% | 8.6% |
| Profit Margin | -148.4% | 7.0% | 5.4% | 7.7% |
| Rev Growth | — | +17.4% | +6.9% | +2.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.53M | 109.76M | 100.41M | 133.92M |
| Total Equity | 1.81B | 546.43M | 592.21M | 571.74M |
| D/E Ratio | 0.00 | 0.20 | 0.17 | 0.23 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -462,848,795 | 42.24M | 40.52M | 39.62M |
| Free Cash Flow | — | 21.56M | 19.96M | 24.65M |